Clinical Trial Update: Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy [Phase 2]

View source ↗

Summary

A Phase 2 presurgical trial of lapatinib in breast cancer to explore determinants of response has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tykerb (lapatinib)

Snippet

Sponsor: University of Pennsylvania | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN